1 not yet recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Ding-Wei Ye: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT - Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer) | Phase 3 | Not yet recruiting | Ding-Wei Ye | 400 | 2025-01-30 | 2025-01-10 |
Abiraterone Acetate (1) · Androgen Antagonists (1) · BID protein, human (1) · Prednisolone (1)
China (1)